Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 7/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.36 |
| ▸ | HRH2 | P25021 | 3/20 | 0.36 |
| ▸ | HRH1 | P35367 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16933531 | 0.90 | GPR119 (0.41) | CHRM5CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL16933687 | 0.88 | CHRM5 (0.42) | CHRM5CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL16933479 | 0.87 | CHRM5 (0.40) | CHRM5CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL16933481 | 0.87 | CHRM5 (0.40) | CHRM5CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL15579458 | 0.83 | PRKAB2 (0.37) | CHRM5CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL16933652 | 0.81 | ACKR3 (0.35) | CHRM5CHRM1CHRM3MEN1KMT2A | |
| SCHEMBL16933698 | 0.80 | JAK2 (0.41) | CHRM5CHRM1CHRM3HRH3 | |
| SCHEMBL16933618 | 0.80 | FLT3 (0.36) | CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL16933631 | 0.79 | CHRM5 (0.39) | CHRM5CHRM1CHRM3HRH3 | |
| SCHEMBL16933699 | 0.79 | HRH3 (0.42) | CHRM5CHRM1CHRM3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114040762-A | Treatment of ciliary disease using inhibitors of glucosylceramide synthase (GCS) | 建新公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM5 4860/4885CHRM1 4870/4885CHRM3 4832/4885 |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, GALC | CHRM5 1317/4885CHRM1 943/4885CHRM3 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.